DOI:
10.1055/s-00000133
Gastroenterologie up2date
LinksClose Window
References
Joensuu H, Eriksson M, Sundby-Hall K. et al.
Survival Outcomes Associated With 3 Years vs. 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
JAMA Oncol 2020;
6: 1241-1246
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.